ARA-290 (Cibinetide) (40 mg Vial) Dosage Protocol
ARA-290 (cibinetide) is an 11-amino-acid peptide derived from erythropoietin (EPO) that retains tissue-protective and anti-inflammatory effects without erythropoietic activity.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (2 mL = 20 mg/mL)
| Week | Daily Dose | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 2 mg (2,000 mcg) | 10 units (0.1 mL) |
| Weeks 2–8 (or up to 16) | 4 mg (4,000 mcg) | 20 units (0.2 mL) |
Frequency: Inject once daily subcutaneously. Clinical studies used 4 mg/day as the target therapeutic dose, with no additional benefit observed at 8 mg. Starting at 2 mg for the first week allows assessment of individual tolerance before reaching the maintenance dose.
Reconstitution Steps
- Draw 2 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl or roll until fully dissolved (do not shake vigorously).
- Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Calculated from the schedule above for a 40 mg vial reconstituted with 2 mL (one injection per day, two swabs per injection).
| Item | 8 weeks | 12 weeks | 16 weeks |
|---|---|---|---|
| Peptide vials (40 mg each) | 6 vials (210 mg total) | 9 vials (322 mg total) | 11 vials (434 mg total) |
| Insulin syringes (U-100) | 56 syringes | 84 syringes | 112 syringes |
| Bacteriostatic water (10 mL bottles) | 12 mL → 2 × 10 mL bottles | 18 mL → 2 × 10 mL bottles | 22 mL → 3 × 10 mL bottles |
| Alcohol swabs | 112 swabs → 2 × 100-count boxes | 168 swabs → 2 × 100-count boxes | 224 swabs → 3 × 100-count boxes |
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 14 days, protect from light |
Important Notes
How This Works
ARA-290 is derived from helix B of EPO and binds the innate repair receptor (IRR — a tissue-protective receptor distinct from EPO's erythropoietic receptor). It produces anti-inflammatory and tissue-protective effects without raising hematocrit.
Potential Benefits & Side Effects
Potential Benefits
- Anti-inflammatory effects via IRR.
- Studied in diabetic neuropathy and sarcoidosis-related neuropathy.
- No erythropoietic effect — separate from EPO's blood effects.
Side Effect Profile
- Generally well-tolerated in trials.
- Mild injection-site reactions.
Lifestyle Factors
- Anti-inflammatory diet complements effects.
- Adequate B-vitamins support nerve health.
Injection Technique
- Subcutaneous, rotate sites.